relief of atherosclerotic occlusive disease may be impossible or contraindicated by the extent or severity of accompanying disease. In transient cerebral ischemia, antiplatelet or antithrombotic drugs are given, and often provide symptomatic relief. Such drugs are also frequently used in coronary and peripheral arterial disease, even when symptomatic improvement does not accompany their use. In many patients with cerebral arterial disease as well, neither anticoagulants nor antiplatelet drugs produce relief of symptoms. The simultaneous use of both antiplatelet and anticoagulant therapy has generally been considered too dangerous, as reflected by the paucity of reports in the literature.
We present here a retrospective study of a group of patients with vascular disease treated with a combina-THERAPY WITH ASPIRIN AND WARFARlWMiller and Lees tion of aspirin and warfarin and review the literature on these therapies.
Clinical Material and Methods
All patients who attended the arteriosclerosis clinic at MIT or were seen by its staff physicians in consultation at the Massachusetts General and New England Deaconess Hospitals during a 13 year period (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) were included in this study. The records of these approximately 1,000 patients were reviewed in extenso to determine how many were treated simultaneously with aspirin and warfarin. Twenty such patients were found. A detailed review of these twenty patients was undertaken using in-hospital records and clinic charts as well as by direct consultation by the authors of those still living and attending the clinic, as of July 1983. Aspirin, 0.6 grams twice daily and warfarin in dosage necessary to maintain the prothrombin time between 16 and 20 seconds was given orally as standard therapy for all patients. This group of patients, except for patient 18, who suffered from rheumatic heart disease, and multiple systemic emboli after valve replacement, had unusually severe disease, with generalized arteriosclerosis affecting multiple organ systems (table 1) . Combined therapy with aspirin and warfarin was used only after failure to achieve clinical improvement or symptomatic relief with more conventional therapies, medical or surgical; or else, in those cases where surgery was indicated but could not be performed because of serious medical contraindications.
The group of 20 patients (table 1) selected for combination therapy included 16 males and 4 females with a mean age of 55 years (range 44 to 81 years). The average duration of therapy was 5.8 years (range 0.5 to 8.75 years). Seven patients were treated for 8 or more years and only a single patient was treated for less than one year. Four of the patients received dipyridamole in addition to the combination therapy.
Of the 20 patients, only one (patient 1) had none of the major risk factors for arteriosclerosis. One patient (patient 9) suffered from diabetes mellitus and required daily insulin injections.
Familial hyperlipoproteinemia occurred in 13 patients, 9 with Type IV and 4 with Type II. These patients, in addition to simultaneous aspirin and warfarin therapy, were treated with the usual dietary restrictions and, where indicated, lipid-lowering drags.
Of the 20 patients, only 1 denied ever having smoked cigarettes. One patient had smoked mostly cigars or a pipe and the remaining 18 patients admitted to smoking the equivalent of a mean of 32 pack years, a conservative number even in the patients' own estimation. However, by the time combination therapy was instituted all except one patient (patient 16) stated that they had stopped smoking completely.
Seven of the 20 patients suffered from hypertension of varying severity. Six of the seven were treated with antihypertensive drugs according to their individual requirements and the 7th patient (patient 13), although hypertensive, was not treated with antihypertensive drugs prior to institution of combination therapy.
The presenting symtoms are listed in table 1 and  summarized in table 2 . Symptoms related to the CNS were the commonest presentation (patients 1-13). Five patients presented with symptoms of peripheral vascular disease (patients 14-18). Finally, two patients had heart disease as the presenting complaint (patients 19 & 20). As far as could be determined, lipid-lowering and antihypertensive therapy was not significantly changed during the follow-up period, nor were the smoking habits of the single cigarette smoker and the insulin dose of the diabetic patient significantly different.
Results
All 20 patients became asymptomatic (with respect to neurological symptoms) or snowed marked clinical improvement (with respect to heart and lower extremity disease) once the combination of aspirin and warfarin was fully established. However, as of July 1983, only 6 patients were still on the combination therapy, while 14 others had stopped for reasons summarized in table 3. Only one patient (patient 9), had the combination therapy discontinued electively by the physician after he had remained asymptomatic for 4'/2 years. Two patients stopped therapy of their own accord; one patient for no special reason other than a personal preference to stop taking all pills, while the other developed a fear of bleeding following an automobile accident in which he had sustained minor injuries.
Six patients had therapy discontinued following acute bleeding, two after intracranial hemorrhage and four following gastrointestinal bleeding. Six patients died during the study (table 3) . There were 2 sudden deaths while on therapy, both clinically compatible with acute myocardial ischemia, although in neither was the diagnosis confirmed at autopsy. One patient died in the immediate post-operative period after having been taken off the combination therapy prior to cholecystectomy for recurrent episodes of biliary colic. One patient died of disseminated carcinoma of the lung.
Complications associated with use of aspirin and warfarin therapy occurred in a total of seven of the 20 patients (table 4). As noted, there were 6 acute episodes of bleeding, two intracranial and four gastrointestinal. These occurred after a mean duration of therapy of 2.7 years with a range of 0.5 to 8 years. Onlyone of these hemorrhagic episodes resulted in death (patient 2), although one intracranial hematoma required evacuation. The diagnosis of hypertension had been made in the latter patient (patient 13), but adequate antihypertensive control was not achieved prior to the institution of combination therapy.
There were two gastric ulcers, one duodenal ulcer, and one episode of gastrointestinal bleeding the origin of which was not identified. All these patients were successfully treated conservatively with replacement of blood, gastric lavage and antacids following cessation of combination therapy.
A graft embolus complicated the course of patient 14 after two years of combination therapy. This re- quired emergency embolectomy, which proved to be successful. For the last 6 years this patient's grafts have remained patent and he has not undergone any further vascular surgery, while remaining on aspirin and warfarin therapy. Patient 18, who had successfully undergone aortoiliac bypass surgery, developed a distal iliac stenosis after 6 years of combination therapy. Percutaneous angioplasty successfully relieved the stenosis and symptoms of claudication. During his eighth year on combination therapy this patient died of an acute myocardial infarction.
Discussion
Our study was retrospective and therefore, of necessity, nonrandom and largely anecdotal. We performed the analysis to test two hypotheses. First, we wanted to learn whether the combination of aspirin with warfarin could be used to treat high risk patients without inevitable disastrous results. Second, we postulated that the use of this drug combination with careful monitoring of the prothrombin time would stabilize the status of patients otherwise intractably symptomatic. All of the patients had remained symptomatic after maximal conventional medical and surgical therapy -the single criterion for treatment with warfarin and aspirin. Even though all the patients were severely symptomatic when placed on the combined therapy, the mean followup period at the time of this writing was 5.8 years, and 14 of 20 patients remain asymptomatic, although only 6 of these are presently continuing with the combined therapy.
Relief of symptoms was most dramatic in the largest subgroup, those patients presenting with recurrent or intractable transient ischemic cerebrovascular symptoms. Furthermore, no patient developed a thrombotic stroke while on simultaneous aspirin and warfarin, although there were 2 episodes of cerebellar hemorrhage, one clearly related to the inappropriate use of the therapy in uncontrolled hypertension. To our knowledge, no previous report has appeared on the simultaneous use of aspirin and warfarin for treatment of recurrent or intractable transient cerebral ischemia. Although the number of patients presenting with peripheral vascular disease in our study was small, and the type of vascular problem variable, the extraordinary response to simultaneous aspirin and warfarin therapy of the patient who had required 12 vascular reconstructive procedures because of recurrent graft thrombosis is worthy of attention (table 1) . Patient 14, a 48 year old male with type IV hyperlipidemia, when first seen in our clinic had undergone more than one vascular procedure each year over the preceding 8 years to maintain the viability of his limbs. Since insti- tution of simultaneous aspirin and warfarin therapy, he has had no further vascular procedures in the last 8 years, apart from a single episode of graft embolus, where the proximal graft pseudointima embolized, occluding the distal anastomosis. The use of anticoagulant or antiplatelet drugs on their own has not been shown to prolong graft patency. 1 Recently however, use of antiplatelet drugs in the perioperative period appears to increase early graft patency rates following saphenous vein coronary artery bypass. 2 We could find no reports, prospective or retrospective, evaluating simultaneous use of aspirin and warfarin in graft patency in peripheral vascular disease.
Simultaneous aspirin and warfarin in patients with prosthetic heart valves is the only use of this therapy which is documented in the literature. Dale et al Although several early studies of patients taking aspirin for rheumatoid arthritis suggested the possibility that aspirin alone might be useful in reducing the incidence of myocardial infarction, 4 more recent reports showed conflicting results. 5 -6 Similarly, the use of antiplatelet drugs in secondary prevention of myocardial infarction, of which there are at least 8 randomized double-blinded trials 7 remains inconclusive, although positive trends in reduction of mortality, non-fatal infarction, and sudden death have been reported in some studies. Long term anticoagulation in patients with ischemic heart disease has been shown to be of little benefit and has largely been abandoned. 8 There are no studies in the use of combined therapy in secondary prevention of recurrent myocardial infarction. In our study, great care was exercised to prolong the prothrombin time only to one and a half times the control value, with minimal variation. Despite this, bleeding was the commonest complication and occurred in 6 out of the 20 patients, an incidence of 30%. Dale et al 9 in a prospective double-blind randomized study of patients with prosthetic heart valves showed that bleeding complications were more frequent in those on simultaneous aspirin and warfarin than in those on warfarin only and that GI bleeding was entirely responsible for this difference. Intracranial bleeding was not more frequent in those patients receiving aspirin in addition to warfarin than in those patients on warfarin alone. In our study, intracranial bleeding occurred in two patients, one of whom died, the only death directly related to combination therapy. However our patients had severe intracerebral arteriosclerosis, and the risk of vessel fracture and subsequent hemorrhage was probably higher than in Dale's cardiac patients. As in Dale's study, gastrointestinal bleeding was our major complication, occurring in four of our 20 patients. This pilot study suggests that when alternative therapies are impossible or have proven to be of no avail in patients suffering from the complications of advanced atherosclerosis, the simultaneous administration of aspirin and anticoagulants may be a valid therapeutic alternative, despite the increased risk of hemorrhage. Only prospective randomized studies can establish quantitatively the risk:benefit ratio of such therapy. Extreme caution must be exercised when embarking on simultaneous aspirin-warfarin therapy in a given patient. Once begun, very close and careful followup of the patients' prothrombin times and clinical status is essential.
